Verastem reports $2.1M net product revenue from AVMAPKI FAKZYNJA launch in first 6 weeks

Verastem, Inc.

AVMAPKI FAKZYNJA co-pack approved May 8, 2025 for KRAS-mutant recurrent LGSOC; $2.1M net revenue in first six weeks.
RAMP 201 trial showed 44% ORR and median DoR 3.3-31.1 months for approved combination.
RAMP 205 dose level 1 in 1L metastatic pancreatic cancer achieved 83% confirmed ORR (10/12).
VS-7375 (KRAS G12D inhibitor) Phase 1/2a trial dosed first patient in U.S.; Fast Track designation granted.
RAMP 301 confirmatory trial enrollment on track for completion by end of 2025; IDMC recommendation expected Q4 2025.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.